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Phosphoinositides (PIs) are lipid second messengers
implicated in signal transduction and membrane traffick-
ing. Seven distinct PIs can be synthesized by phospho-
rylation of the inositol ring of phosphatidylinositol
(PtdIns), and their metabolism is accurately regulated
by PI kinases and phosphatases. Two of the PIs, PtdIns3P
and PtdIns(3,5)P2, are present on intracellular endosomal
compartments, and several studies suggest that they
have a role in membrane remodeling and trafficking. We
refer to them as ‘endosomal PIs’. An increasing number of
human genetic diseases including myopathy and neuro-
pathiesareassociatedtomutationsinenzymes regulating
the turnover of these endosomal PIs. The PtdIns3P and
PtdIns(3,5)P2 3-phosphatase myotubularin gene is
mutated in X-linked centronuclear myopathy, whereas
its homologs MTMR2 and MTMR13 and the PtdIns(3,5)P2
5-phosphatase SAC3/FIG4 are implicated in Charcot–
Marie–Tooth peripheral neuropathies. Mutations in the
gene encoding the PtdIns3P 5-kinase PIP5K3/PIKfyve
have been found in patients affected with Franc xois–
Neetens fleck corneal dystrophy. This review presents
the roles of the endosomal PIs and their regulators and
proposes defects of membrane remodeling as a common
pathological mechanism for the corresponding diseases.
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In eukaryotic cells, spatiotemporal regulation of cellular
organization and cell–cell communication require tightly
regulated second messengers and membrane microdo-
mains.Phosphoinositides(PIs)are lipid second messengers
implicated in signal transduction and membrane trafficking
through recruitment of protein effectors to their site of
action (1). Phosphatidylinositol (PtdIns) is one of the major
lipids within the cell and is composed of different chemical
moieties: two fatty acid tails anchor the PtdIns molecule
into cellular membranes and are linked through a glycerol
backbone and an inorganic phosphate to the inositol head
group. This inositol sugar ring directs into the cellular lumen
and can be phosphorylated on positions three, four and five,
resulting in seven possible PIs. Interconversions between
different PIs are controlled by PI kinases and phosphatases.
A plethora of reports showed their involvement in signal
transduction, but pioneer studies, especially in yeast,
have shown that among the various PIs, PtdIns3P and
PtdIns(3,5)P2 areinvolvedinmembranetrafficking (2,3).We
will focus here on these so-called ‘endosomal PIs’,
PtdIns3P and PtdIns(3,5)P2.P t d I n s 3 P was first discovered
through the characterization of PI kinases in fibroblasts and
by radioactive labeling of astrocytoma cells, while studies in
osmotically stressed yeast strains and in resting mouse
cells led to the detection of in vivo PtdIns(3,5)P2 pools (4–7).
Their regulators are implicated in human genetic diseases
including several neuromuscular disorders. The impact of
PtdIns3P and PtdIns(3,5)P2 metabolism unbalance on the
phenotypic manifestations remains poorly understood, but
one may hypothesize that the diseases share some com-
mon pathomechanisms involving abnormal trafficking. Phe-
notypesseen inpatientsmay thus highlightnew roles of PIs
and implicated regulators, and conversely, the known roles
of PIs and regulators may help to understand the patho-
physiology of the related diseases.
The canonical PIs turnover pathway implicates the phos-
phorylation of PtdIns into PtdIns3P by the class III PI
3-kinase (PIK3C3, also called VPS34 in Saccharomyces
cerevisiae). PtdIns3P is subsequently phosphorylated by
the type III PI 5-kinase (PIP5K3, also called PIKfyve, and
FAB1 in S. cerevisiae) into PtdIns(3,5)P2, the reverse
reaction being catalyzed by the phosphatase SAC3 (the
ortholog of S. cerevisiae FIG4). PtdIns(3,5)P2 can be de-
phosphorylated by the 3-phosphatase myotubularins
(MTMs), leading to the production of PtdIns5P.M y o t u b u l a r -
ins also dephosphorylate PtdIns3P into PtdIns (Figure 1).
Other alternative pathways have been suggested by in vitro
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of PtdIns3P and PtdIns(3,5)P2 through the action of class II
PI 3-kinase, 4-phosphatase and 5-phosphatase acting on
PtdIns(3,4,5)P3 or class I PI 3-kinase acting on PtdIns5P,
respectively (8,9).
Production of PtdIns3P by PIK3C3/hVPS34,
a Candidate for Schizophrenia and
Autophagy-Related Diseases
PtdIns3P, the product of PIK3C3, is involved in membrane
transport and dynamics. It is highly enriched on early
endosomes and in the internal vesicles of multivesicular
bodies (MVBs) and can recruit proteins containing FYVE,
PX or PH motifs (10). Among them, early endosome
antigen 1 (EEA1), a protein essential for endosome fusion,
is recruited to early endosomes by Rab5-GTP and PtdIns3P
(11). Moreover, the complex formed by PIK3C3 and its
regulatory subunit PIK3R4 (also called p150 and VPS15 in
S. cerevisiae) produces PtdIns3P and binds Rab5 (12).
Hepatocyte growth factor regulated tyrosine kinase sub-
strate (HRS), another FYVE domain protein, is recruited to
early endosomes/MVBs by PtdIns3P and controls the first
steps of receptor sorting and internalization within the
MVBs (13–15). VPS34 also regulates protein sorting to the
lysosome in addition to vacuole segregation during mitosis
in S. cerevisiae and is involved in membrane homeostasis
asshownbytheenlargedvacuolesofSchizosaccharomyces
pombe strains deleted for the Vps34 gene and in cultured
mammalian cells treated with small interfering RNA
(siRNA) against PIK3C3 (2,16–18). In addition to PtdIns3P
roles and localization at intracellular compartments, a regu-
lated pool of PtdIns3P is specifically formed at the plasma
membrane of cultured muscle cells upon insulin stimula-
tion through activation of the small GTP-binding protein
TC10 and is involved in the translocation of the glucose
transporter protein GLUT4 to the plasma membrane (19).
Production of PtdIns3P by PIK3C2A may also medi-
ate ATP-dependent priming of neurosecretory granule
Figure 1: EndosomalPIstructure,
metabolism, subcellular localiza-
tion and associated human dis-
eases. A) Chemical structure of
PtdIns that can be phosphorylated
on position 3, 4 and/or 5. B) In-
terconversion of PtdIns3P and
PtdIns(3,5)P2 is catalyzed by kinases,
PIK3C3 (VPS34 in Saccharomyces
cerevisiae) and PIP5K3 (also called
PIKfyve and FAB1 in S. cerevisiae),
and phosphatases, SAC3 (FIG4 in
S. cerevisiae) and myotubularins,
including MTM1, MTMR2 and
the inactive phosphatase MTMR13.
Associated human diseases are
shown in blue. C) Subcellular local-
ization of PtdIns3P (in green) and
PtdIns(3,5)P2 (in red) are shown in
the endocytic pathway: early endo-
somes, sortingendosomes, recycling
endosomes for receptor recycling
and MVBs/late endosomes and
lysosomes for degradation. The lo-
calization of PtdIns(3,5)P2 is hypo-
thetical. Based on works performed
in yeast, Drosophila, Caenorhabditis
elegans and mammalian cells,
PtdIns(3,5)P2 should be present at
the external membrane of late
endosomes and at lysosomes. The
destiny of lysosomes is not known
but rather hypothetical based on the
same studies.
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translocation of storage compartments under stimulation.
Studies on Caenorhabditis elegans also point to a role of
PIK3C3 and PtdIns3P at plasma membrane and nuclear
membrane as deletion of CePIK3C3 results both in endo-
cytosis defect and in expansion of the outer nuclear
membrane (21,22). Therefore, PtdIns3P and PIK3C3 are
required for membrane recruitment of several proteins
involved in the control of vesicular transport and intracel-
lular protein sorting.
Moreover, it is proposed that PIK3C3 and its product
PtdIns3P are involved in the control of autophagy vesicles.
This is supported by the finding that PI 3-kinase inhibitors
impair autophagy, that exogenous PtdIns3P rescues these
autophagy defects and that PIK3C3 interacts with proteins
involved in the autophagy process like Beclin 1 (23,24).
Autophagy is altered in many human diseases like cancer,
some myopathies where autophagic vacuoles accumulate
(for example in Danon’s disease) and a number of neuro-
degenerative disorders where the accumulation of mis-
folded proteins could result from a defect in autophagy
(25). No causative mutation in PIK3C3 has been found yet
in these types of diseases. However, three accessory
subunits of the PIK3C3–PIK3R4 complex are tumor sup-
pressors (Beclin 1, Uvrag and Bif-1) (26). A rare variant in
the promoter of PIK3C3 gene has been reported to be
associated with bipolar disorder and schizophrenia in
a candidate gene study (27,28). This variant occurs within
an octamer sequence containing an ATTT core motif found
in promoters that bind to members of the Pit-1, Oct, unc-
86 (POU) transcription factor family and was observed to
induce binding of an unidentified nuclear protein by gel
shift assay (28). However, the association data appear
rather confusing in different populations; statistical signi-
ficance was not corrected for multiple testing and the
association to bipolar disorder or schizophrenia should thus
be considered tentative at best. A link between PIK3C3
and bipolar disorder might be consistent with the obser-
vation that PIs are potential targets for the therapeutic
effect of lithium in bipolar disorder.
Production of PtdIns(3,5)P2 by PIP5K3/PIKfyve
and Corneal Fleck Dystrophy
Heterozygous mutations of the PIP5K3 gene have been
found in cases of autosomal dominant Franc xois–Neetens
corneal fleck dystrophy (CFD, OMIM 121850), which is
characterized by abnormal swollen keratocytes with enlarged
vesicles of unknown origin in the cornea (29). Except for an
occasional patient with minor photophobia, patients have
a normal vision. The majority of mutations found in Franc xois–
Neetens CFD are nonsense or frameshift heterozygous
mutations that result in a protein deleted for its kinase
domain. Whether this leads to a dominant negative effect
or a haploinsufficiency has not been determined yet (29).
An important implication of PIP5K3 in vacuole size regula-
tion has been underlined. Indeed, the yeast vacuole,
analogous to the mammalian lysosome, is enlarged in
Fab1 mutants (3,30). FAB1 is important for vacuole size
regulation, protein sorting at MVB and vacuole acidification
(31,32). Mutants deleted for Vac7 or Vac14, which encode
two known activators of FAB1, recapitulate enlarged
vacuoles and acidification defects of Fab1-deleted strains
(33,34). Overexpression of a kinase-defective PIP5K3
mutant, suppression of PIP5K3 by siRNA and drug-specific
inhibition of PIP5K3 enzymatic activity produce abnormal
vesicles described as enlarged early/late endosomes (35–
37). PIP5K3 suppressed cells, as well as Drosophila and
C. elegans PIP5K3mutants where enlarged late endosomes/
lysosomes are also present, do not show receptor signal-
ing and protein degradation defect, respectively, suggest-
ing that PIP5K3 has a role in the retrieval of membranes
exiting the endosomal pathway from early and late endo-
somes and lysosomes (37–39). Indeed, Rutherford et al.
observed that PIP5K3 regulates endosome-to-trans Golgi
network (TGN) retrograde transport and PIP5K3 interacts
with p40, a RAB9 effector implicated in retrograde traffic
from the late endosome (37,40). This mechanism could be
mediated through a putative role of PtdIns(3,5)P2 in
membrane fission as suggested in wild-type yeast where
PtdIns(3,5)P2 levels increase upon hyperosmotic shock
and lead to vacuolar fragmentation (4,33). Subcellular
localization of PtdIns(3,5)P2 is still unclear because of the
lack of well-characterized tools to detect it and is based on
indirect evidences obtained inyeast,Drosophila,C.elegans
and mammalian cells. Part of the roles of PIP5K3 are
transduced by PtdIns(3,5)P2 effectors (41). These include
Epsin N-terminal homology 3 (ENT3), ENT5 and vacuolar
protein sorting 24 (mVPS24) for MVB sorting and autoph-
agy related 18 (ATG18) for membrane retrograde transport
and partitioning of the vacuole (42–44). ATG18 has also
been implicated in membrane and protein retrieval from
the preautophagosomal structures (45). PIP5K3 has been
described as a regulator of insulin-stimulated GLUT4
vesicle translocation to the plasma membrane following
its phosphorylation by protein kinase B and as an inhibitor
of exocytosis in neurosecretory cells (46,47). Therefore,
numerous organisms recapitulate the CFD phenotype of
vesicle enlargement. Part of the underlying cause of this
disease may be a defect in membrane fission or retrieval
from endosomes and membrane storage compartments.
Heterozygous PIP5K3 mutations result in a mild phenotype
in the eye. It is not excluded that other tissues contain
vacuoles in CFD patients, and PIP5K3 homozygous muta-
tions may be found in more invalidating diseases.
PtdIns3P and PtdIns(3,5)P2 Dephosphorylation
and Charcot–Marie–Tooth Diseases
Charcot–Marie–Toothdiseases(CMT)areaheterogeneous
group of genetic peripheral neuropathies affecting motor
and sensory nerves and are characterized by progressive
1242 Traffic 2008; 9: 1240–1249
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velocity (NCV) tests are used to differentiate between the
demyelinating forms of CMT (types 1, 3 and 4; forearm
motor NCV  38 m/second) and the axonal form of CMT
(type 2; NCV  38 m/second). Autosomal recessive forms
of demyelinating CMT are collectively designated CMT4
(48). Nerve biopsies from CMT4B patients are character-
ized by remarkable focally folded myelin sheaths (49).
Myelin in the peripheral nervous system is generated
and maintained by myelinating Schwann cells. This highly
specialized cell type enwraps segments of axons with
multiple layers of its plasma membrane.
SAC3/FIG4 and CMT4J neuropathy
Compound heterozygous mutations of the human SAC3
gene have been identified in four unrelated patients with
autosomal recessive CMT neuropathy named CMT4J
(OMIM 611228) (50). These patients presented one
allele encoding an inactivating missense mutation I41T
upstream of the SAC phosphatase domain, while the other
allele carried a truncating mutation located upstream or
within the SAC domain.
The identification of SAC3 mutations has been allowed by
the observation of phenotype similarities between CMT
patients and the ‘pale tremor mouse’. This mouse contains
an insertion of a transposon into an intron of the SAC3
gene resulting in a loss of the protein and presents
neuronal degeneration in the central nervous system,
peripheral neuropathy and diluted pigmentation. Cultured
fibroblasts from pale tremor mice are filled with enlarged
late endosomes/lysosomes and show a reduced level of
PtdIns(3,5)P2 compared with wild type in apparent dis-
crepancy with the PtdIns(3,5)P2 5-phosphatase function
ofSAC3(50,51).ThisphenotypemimicsPIP5K3/FAB1sup-
pression and is similar to FIG4-deficient yeast strains (52).
There are several possible explanations for the unexpected
PtdIns(3,5)P2 decrease following SAC3 mutations. SAC3
interacts with one PIP5K3 activator VAC14 and has been
shown to be required for the hyperosmotic shock-induced
elevation of PtdIns(3,5)P2 levels (51,53,54). The absence
of SAC3 may then result in defects in VAC14-dependent
PIP5K3 activation, as sustained by the similar phenotype of
the mouse mutant lacking VAC14 (55). Alternatively, SAC3
may be a direct activator of PIP5K3. The SAC3 I41T mutant
found in CMT4J patients is unable to fully activate PIP5K3
kinase activity in a complementation assay of FIG4-deleted
yeast strains subjected to hyperosmotic shock (50). In the
pale tremor mice, peripheral nerves are affected and
vacuoles accumulation precedes cell loss in the central
nervous system. Functional analysis suggests that such
vacuoles could originate from a lack of retrograde transport
from late endosomes/lysosomes, similarly to CFD. Neuro-
degeneration may be related to the role of endosomal
vesicles in delivering membrane components to dendritic
spines or, if degradation is affected, to a deleterious
accumulation of proteins. In the peripheral nervous sys-
tem, in addition to axonal degeneration, it is expected that
impaired conduction velocity observed in pale tremor mice
and in CMT4J patients reflects defects in myelin sheath
formation, as it is the case in other forms of demyelinating
CMT.
MTMR2 and CMT4B1 demyelinating neuropathy
The gene coding for myotubularin-related protein-2
(MTMR2) was found mutated in autosomal recessive
demyelinating neuropathy CMT type 4B (CMT4B1, OMIM
601382) (56). MTMR2 is part of the large family of
myotubularins, conserved in yeast, and encompassing 14
membersinhuman(myotubularinMTM1andmyotubularin-
related proteins MTMR1 to 13) (57). Eight of the human
myotubularins are 3-phosphatases sharing specificity
toward PtdIns3P and PtdIns(3,5)P2 (58–60). The myotubu-
larin family also encompasses inactive phosphatases that
lack key residues in the catalytic loop but are conserved
through evolution. CMT4B1-causing mutations in MTMR2
are located all along the gene, giving rise to truncated or
inactive proteins (56,61).
Mtmr2 knockout mouse models develop a mild CMT4B1-
like neuropathy and azoospermia. Myelination of peripheral
nerves is abnormal in the knockout mice, with myelin
outfoldings and recurrent loops originating at paranodal
regions(62–64). Schwann cell-specific ablation ofMtmr2 is
sufficient to mimic the CMT4B1 phenotype in mice, while
motoneuron-specific ablation has no effect, strongly sug-
gesting that the myelinating Schwann cell is initially
affected in CMT4B1 (62,63). Moreover, MTMR2 has
recently been reported to play a role in cell proliferation
and survival of Schwann cells in primary cultures (65).
Overexpression of human MTMR2 in yeast leads to
enlarged vacuoles and, in hypoosmotically stressed COS
cells with increased levels of PtdIns(3,5)P2, MTMR2 is
recruited to the membrane of vacuoles formed under
these conditions (66,67). This redistribution of MTMR2 is
dependent on its PH-GRAM domain, which has been
proposed to bind PtdIns(3,5)P2 and/or PtdIns5P (68–70).
These data suggest that endogenous MTMR2 could be
implicated in vacuolar transport and fusion through its
phosphatase activity toward PtdIns(3,5)P2 and PtdIns3P.
MTMR2 may be regulated by lipid and protein interactors.
The PH-GRAM domain of several MTMR2 homologs
mediates a PtdIns3P/PtdIns5P-dependent oligomerization
and a PtdIns5P-specific activation (71). Moreover, MTMR2
is also regulated by heterodimerization with inactive phos-
phatase homologs, MTMR5/SBF1 and MTMR13/SBF2
(72–74). MTMR13 is also mutated in CMT4B2, suggesting
that MTMR2/MTMR13 interaction is important in
Schwann cells. Interestingly, the neurofilament light chain
NF-L, mutated in dominant axonal CMT2E or dominant
demyelinating CMT1F, interacts with MTMR2 in Schwann
cells as well as in neurons (75,76). MTMR2 also binds to
discs large 1 (Dlg1)/synapse-associated protein 97 (SAP97)
in myelinated nerve fibers (62). Dlg1/SAP97, a membrane
associated guanylate kinase-like (MAGUK), is a scaffolding
protein specifically detected in Schwann cells at the node/
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loops originate in CMT4B1 (62). Dlg1 homologs have been
located in several types of cellular junctions and play
important roles in cell polarity and membrane addition
(77). Loss of MTMR2/Dlg1 interaction in Schwann cells
may impair membrane homeostasis in the paranodal
region, thereby leading to myelin defects. The functions
of MTMR2 and of its inactive partner MTMR5 may also be
important in testis as both MTMR2 and MTMR5 ablations
in mice lead to defects in spermatogenesis (62,78). It has
been proposed that Mtmr2-deleted mice show azoosper-
mia because of a loss of cell adhesion between Sertoli and
germ cells within the seminiferous epithelium (62). This
is consistent with the finding that MTMR2 interacts with
c-src, a non-receptor protein tyrosine kinase that is part of
the N-cadherin/b-catenin functional complex at adherens
junctions (79). These findings support the idea that the
association between MTMR2 and MTMR5 could be of
physiological significance in spermatogenesis.
MTMR13 and CMT4B2 demyelinating neuropathy
Mutations in the MTMR13/SBF2 gene, which encodes
a catalytically inactive member of the myotubularin family
involved in heterodimerization with MTMR2, cause
CMT4B2 (OMIM 604563), which has similar pathological
features to CMT4B1, with additional glaucoma in some
patients (80,81). Five distinct CMT4B2-causing mutations
have been reported in the MTMR13 gene and are pre-
dicted to result in the loss of MTMR13 protein or to
a truncated product (80–82).
Mtmr13 knockout mice reproduce myelin outfoldings in
peripheral nerves as the pathological hallmarks of CMT4B2
(83,84). The physical interaction between MTMR2 and
MTMR13 offers a molecular explanation for the similar
phenotypes in CMT4B1 and CMT4B2. In in vitro and in vivo
experiments, homodimeric MTMR2 interacts with homo-
dimeric MTMR13 to form a tetrameric complex. This
association dramatically increases the enzymatic activity
of MTMR2 toward PtdIns3P and PtdIns(3,5)P2 (72). Fur-
ther regulation may be derived through redirecting the
subcellular localization of the active enzyme MTMR2
by association with MTMR13 (72). In the absence of
MTMR13, MTMR2 PI 3-phosphatase activity may be
misregulated or mislocalized, leading to altered levels of
PtdIns3P and/or PtdIns(3,5)P2 and subsequent membrane
trafficking defects.
PtdIns3P and PtdIns(3,5)P2 Dephosphorylation
by MTM1 and X-Linked Centronuclear
Myopathy
Numerous mutations of the myotubularin (MTM1) gene
have been identified in patients affected with X-linked
centronuclear myopathy, also called myotubular myopathy
(XLCNM, OMIM 310400) (85). XLCNM is a very severe
congenital myopathy associated with generalized muscle
weakness and hypotonia at birth. The histopathology of
skeletal muscle reveals small rounded fibers with central
nuclei. This pattern is somewhat similar to the structure of
fetal myotubes, while normal muscle fibers have periph-
erally located nuclei. About 200 different MTM1 mutations
have been reported in more than 300 unrelated families
(86,87). They are distributed all along the gene and result in
decreased or absent MTM1 in cell lines in the majority of
cases (88). Almost all the truncating mutations are asso-
ciated with a severe form of XLCNM, whereas missense
mutations are sometimes associated with a milder form of
the disease. The hypothesis that the muscle impairment
reflects an altered PI regulation is supported by the
characterization of a patient with a severe phenotype ex-
pressing an inactive MTM1 protein at normal level (59,88).
The Mtm1 knockout mice recapitulate the histopatholo-
gical signs of XLCNM and show a progressive myopathy
starting a few weeks after birth, while muscle histology
appears normal at birth (89). This suggests that the
disorganized appearance of the muscle fibers is explained
by a defect in structural maintenance rather than an
impairment in myogenesis as previously hypothesized.
As MTM1 homologs are mutated in CMT neuropathies,
one could have thought that the muscle weakness re-
flected a nerve conduction defect. However, specific
ablation of the gene in skeletal muscle showed that it is
the primary tissue involved in the pathology (89). The
C.elegans genome contains six MTM genes, three of which
code for active enzymes. Null mutations in the closest
homologue of MTM1 are lethal, and CeMtm-1 knockdown
by RNA interference can correct the endocytic defect of
CeVps-34 mutant worms (22). This is consistent with a role
of MTM1 in negative regulation of PtdIns3P levels. More-
over, mutations or knockdown of mtm-3, mtm-6 and mtm-
9 (the latter encoding a catalytically inactive protein) lead to
reduced fluid-phase uptake into coelomocytes (22,90). A
recent study has shown a colocalization of MTM1 with
RAB5 and RAB7 endosomes where it associates with the
complex formed by PIK3C3 and PIK3R4 to presumably
regulate the PtdIns3P endosomal pool (91). This observa-
tion has been made after saponin extraction of the cells,
a method known to preserve membrane ultrastructure
while extracting the MTM1 cytosolic pool. Stimulation of
cells by the epidermal growth factor provokes a transloca-
tion of MTM1 to the late endosomal compartment depend-
ent of PtdIns(3,5)P2 production (70). Artificial targeting of
MTM1 to RAB5-containing endosomes induces microtu-
bule-dependent tubularization of the endosomal network,
suggesting that MTM1 at endosomes may impact on
membrane remodeling and retrieval, probably through
the function of its substrates, PtdIns3P and PtdIns(3,5)P2
(92). A role of myotubularins at the plasma membrane is
also suspected as overexpression of the MTM1 protein in
mammalian cells leads to altered shape and plasma
membrane projections and as MTM1 localizes to Ras-
related C3 botulinum toxin substrate 1 (RAC1)-induced
plasma membrane ruffles (93,94). Thus, MTM1 may play
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specific sites of action are not yet defined. Defects in
membrane remodeling could be the underlying cause of
X-linked centronuclear myopathy.
Tissue Specificity of Endosomal PIs Diseases
It is striking to note that ubiquitously expressed PI regu-
lators acting in the same pathway are involved in pathol-
ogies affecting different tissues. This is especially
noteworthy for MTM1 and MTMR2, which are two very
close homologs (65% sequence identity) with similar
enzymatic activity and which are implicated in diseases
affecting two different tissues, skeletal muscles for MTM1
in XLCNM and Schwann cells in peripheral nerves for
MTMR2 in CMT4B1, as emphasized by corresponding
tissue-specific ablation experiments in both knockout
mice. A first explanation could consist in differential
regulation of expression between MTM1 and MTMR2.
Even if ubiquitous, MTM1 is more expressed in skeletal
muscles (94). MTM1 and MTMR2 present an inversed
expression pattern during myogenesis: MTMR2 is ex-
pressed in the C2C12 mononucleated myoblast cells and
decreases during the differentiation process, whereas
MTM1 is increased at the RNA and protein level during
myoblasts fusion in culture (88,93). Conversely, mouse
MTMR2 was found to be particularly abundant in the
neurons and Schwann cells of the peripheral nervous
system (61,95). Suggestion for a specific protein function
is based on the observation that subcellular localization
differs between myotubularins. In transfected cells,
MTMR2 is more concentrated around the nucleus com-
pared with MTM1 (67,93). Such results suggest that
different myotubularins may regulate different PI pools.
A thirdpossibility for tissue specificity couldbe interactions
with tissue/cell-specific proteins. Thus, discs, large homo-
log 1 (DLG1) may be a Schwann cell-specific interactor that
recruits and locally concentrates MTMR2 at paranodes to
regulate membrane trafficking and membrane addition.
Heterodimers of active and inactive myotubularins may
also occur in specific tissues or cells (Schwann cells for
MTMR2/MTMR13 and Sertoli cells for MTMR2/MTMR5),
thus determining a tissue-specific activation or regulation
of the active myotubularin partner. No muscle-specific
partner is known for MTM1.
Common Pathological Mechanism of
Endosomal PI Diseases
CMT neuropathies types 4B1, 4B2 and 4J, X-linked cen-
tronuclear myopathy and a rare form of corneal dystrophy
are caused by mutations in regulators of endosomal PIs.
This pathway may also be involved in autophagy-related
disorders and even in psychiatric diseases. PtdIns3P and
PtdIns(3,5)P2 and their regulators all share a common
function in membrane dynamics, with a possible implica-
tion in membrane fission and retrieval. Altered levels
of PtdIns(3,5)P2 and PtdIns3P, following a loss of the
MTMR2/MTMR13 complex in patients affected with
CMT4B1/B2, may cause a defective transport of mem-
branes between a storage compartment and myelin
sheaths. Membrane fission is essential for membrane
retrieval, and fission defects may also be the underlying
cause of CMT dominant intermediate type B (CMTDIB)
because of missense mutations in dynamin 2 (DNM2),
a large GTPase involved in the tubulation of membranes
and in the release of newly formed vesicles (96).
Decreased levels of PtdIns(3,5)P2 caused by mutations in
PIP5K3 and SAC3 genes in CFD and CMT4J patients may
lead to a defect of membrane retrieval from late endosomal
compartments, inducing vacuolization and perturbation of
the late endosome–lysosome pathway. Abnormal regula-
tion of the late endosome–lysosome pathway could also
contribute to neurodegeneration in other forms of CMT
neuropathies like the dominant axonal CMT2B associated
with mutations in RAB7, a GTPase implicated in the
transport of proteins to lysosomes and the dominant
demyelinating neuropathy CMT1C caused by mutations
in the E3 ubiquitin ligase lipopolysaccharide-induced TNF
factor (LITAF) that targets membrane proteins for lyso-
somal degradation through a monoubiquitination mecha-
nism (97,98). Likewise, XLCNM with mutations in MTM1
may be caused by membrane remodeling alterations. This
hypothesis is sustained by the findings that DNM2 is also
mutated in an autosomal dominant form of centronuclear
myopathy and that mutations of amphiphysin 2 (BIN1)
have recently been identified in patients with an autosomal
recessive form of CNM (99,100). BIN1 is involved in
membrane remodeling by sensing and promoting mem-
brane curvature. MTM1, DNM2 and BIN1 may then be
necessary for the remodeling and the delivery of mem-
branes to T-tubules, which are plasma membrane
invaginations implicated in excitation/contraction coupling
in muscle fibers. Perturbation of T-tubules maintenance
and/or endocytic membranes may represent one of the
primary causes of CNM. However, the cause of the
centralization of nuclei in the muscle fibers of CNM
patients remains elusive. The fact that MTM-related pro-
teins and DNM2 are mutated in both centronuclear myo-
pathies and CMT neuropathies further points to a common
mechanism involving PIs and membrane retrieval in skel-
etal muscle and peripheral nerve maintenance.
Conclusions
A significant amount of work has recently highlighted a role
for the endosomal PIs in membrane retrieval and their
implication in human diseases. This leads to the emerging
concept that the associated diseases may be caused by
altered membrane remodeling and retrieval at plasma
membrane and membrane storage compartments. Addi-
tionally, PtdIns3P and PtdIns(3,5)P2 m a ya l s oh a v er o l e s
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where than on endosomes. Questions remain about the
mechanisms responsible for PtdIns3P- and PtdIns(3,5)P2-
dependent membrane remodeling. Tissue-specific interac-
tors of these endosomal PIs are probably involved in the
tubulation and scission of membranes and in the transport
of the resulting vesicles to correct locations in cells. Such
interactors are interesting candidates for centronuclear
myopathies and CMT neuropathies for which several
responsible genes still remain to be identified.
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